Evaluation of Risk Factors for Antipsychotic Polypharmacy in Inpatient Psychiatry Units of a Community Hospital: A Retrospective Analysis

Community Mental Health Journal
Shreedhar PaudelLiliana Markovic

Abstract

Antipsychotic polypharmacy (APP) is a common practice while treating severe mental illness but the benefits of APP over antipsychotic monotherapy is controversial. This is a retrospective analysis comparing risk factors for people on APP and those on non-APP in inpatient psychiatry units. Two years data with 72 people in non-APP group and 82 people in APP group were analyzed quantitatively. The diagnoses of schizoaffective disorder (OR 11.5), schizophrenia (OR 4.65) and depression (OR 0.31), and history of > 2 psychiatric admissions (OR 3.2) and > 2 psychiatric emergency visits (OR 2.87) in 2 years were studied as potential risk factors for APP. Similarly, history of violence (OR 1.7) and history of substance abuse (OR 0.51) were also studied. Schizophrenia spectrum disorder, higher number of psychiatric hospitalizations, and psychiatric emergency visits were positively associated while depression and substance abuse were negatively associated with APP in our study.

References

Aug 25, 2004·The Journal of Clinical Psychiatry·Stefan WeinmannWolfgang Gaebel
Dec 31, 2004·The American Journal of Psychiatry·Richard C JosiassenRita A Shaughnessy
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Julie A KreyenbuhlFrederic C Blow
Dec 7, 2007·The Journal of Clinical Psychiatry·Troy A MooreAlexander L Miller
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Andrea CiprianiCorrado Barbui
May 9, 2012·Expert Opinion on Drug Safety·Juan A GallegoChristoph U Correll
Jun 22, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang Fleischhacker, Hiroyuki Uchida
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Aug 30, 2012·The Psychiatric Clinics of North America·Christoph U Correll, Juan A Gallego
Feb 16, 2013·Journal of Psychopharmacology·Marc W H Lochmann van BennekomFrans G Zitman
Oct 17, 2014·Psychiatric Services : a Journal of the American Psychiatric Association·Dawn I VelliganKathleen Fairman
May 3, 2015·The British Journal of Psychiatry : the Journal of Mental Science·Mark Taylor, Udayanga Perera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here